Immunodeficiency 11b With Atopic Dermatitis C4539957
A combined immune deficiency disorder with atopic dermatitis (severe eczema). It often begins in early childhood and requires coordinated care for both skin and immune system management.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Recurrent bacterial infections
(immunologic)Atopic dermatitis
(integumentary)Elevated serum IgE
(immunologic)Autoimmune manifestations
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Topical corticosteroids and calcineurin inhibitors
First-line topical anti-inflammatory therapy for atopic dermatitis component, with corticosteroids for acute flares and tacrolimus or pimecrolimus for maintenance and sensitive areas.
Biologic therapy (Dupilumab)
Monoclonal antibody targeting IL-4 and IL-13 pathways addresses the underlying type 2 inflammation in atopic dermatitis and may benefit associated immunodeficiency manifestations.
Additional treatment options
Skin barrier optimization and trigger avoidance
Daily moisturization with emollients, gentle cleansing practices, and identification and avoidance of personal triggers (allergens, irritants, temperature extremes) to reduce disease burden.
lifestyleImmunoglobulin replacement therapy
IV or subcutaneous immunoglobulin supplementation addresses the immunodeficiency component, providing passive humoral immunity and may reduce infection frequency and severity.
medicationPsychological support and itch management
Cognitive-behavioral therapy and itch-relief strategies address the significant psychosocial burden of chronic atopic dermatitis and immunodeficiency, including sleep disturbance and quality of life impact.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Immunodeficiency 11b With Atopic Dermatitis C4539957?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Immunodeficiency 11b With Atopic Dermatitis C4539957. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy